Top ▲

CHAPLE disorder; CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)

Disease ID:1289
Name:CHAPLE disorder; CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)
Associated with:0 target
1 immuno-relevant ligand
Description
This is an ultra-rare and life-threatening disorder that is caused by hyperactivation of the complement pathway due to a loss of functional CD55 protein.
Database Links
OMIM: 226300
Orphanet: ORPHA566175

Targets

No target related data available for CHAPLE disorder; CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (PLE)

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
pozelimab
Immuno Disease Comments: Pozelimab is FDA aproved to treat children and adults with CHAPLE disorder.
Clinical Use: Pozelimab is in clinical development to determine safety and efficacy in the treament of complement-mediated inflammatory conditions. The FDA approved pozelimab to treat the ultra-rare inflammatory condition, CHAPLE disorder, in August 2023. | View clinical data